Depemokimab is an ultra-long-acting anti-IL-5 mAb given twice yearly that reduces asthma exacerbations for patients with severe eosinophilic asthma in the SWIFT1 and SWIFT2 phase 3 trials. The gene discussed is IL5; the disease is asthma.